Breast oncology is moving fast, and ESR1 mutations are now at the center of a major shift in endocrine therapy.
In Episode 10, Dr. Jason Mouabbi and Dr. Paolo Tarantino break down how ctDNA, oral SERDs, new combinations, and emerging endocrine therapies are changing treatment decisions in HR-positive breast cancer. They also tackle one of the biggest questions in the field: when should clinicians act on molecular progression before it shows up on scans?
Topics discussed:
• Why ESR1 mutations matter in endocrine resistance
• SERENA-6 and ctDNA-guided treatment switching
• Oral SERDs in monotherapy and combination
• EMBER-3, ELEVATE, and evERA
• Balancing efficacy, toxicity, and treatment sequencing
• Emerging therapies beyond SERDs, including CERANs and next-generation SERMs
• What comes next for endocrine therapy in breast cancer
🎙️ Hosted by Dr. Jason Mouabbi & Dr. Paolo Tarantino
🎧 Watch the full episode and follow The Breast Friends Podcast for more conversations on the latest in breast oncology - https://youtu.be/5Z7a3HkDsG4
#BreastFriends #JasonMouabbi #PaoloTarantino #BreastCancer #ESR1 #HRPositive #OralSERD #ctDNA #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia
